CRCL – The Center for Cancer Research of Lyon is a research structure affiliated with Claude Bernard Lyon 1 University, the French national health and research bodies Inserm and CNRS, the Léon Bérard Comprehensive Cancer Center of Lyon (CLB) and with the University Hospital of Lyon (HCL) as clinical partner. The CRCL was officially created in January 2011, comprises 17 teams, totaling over 390 people, including 110 researchers and teaching researchers. The CRCL is organized around three departments focused on tumoral escape, information flow in the cancer cell and Immunity-microenvironment-virus. The aim of the CRCL is to facilitate the transfer of knowledge gained from cancer research to clinical application in oncology and to develop teaching and training.
Centre MURAZ is one of the oldest multidisciplinary biomedical research centers in Francophone West Africa. Having been the cornerstone of research for health OCCGE (Organisation de coopération et de coordination pour la lutte contre les grandes endémies), the Centre MURAZ remains the engine of health research from the Ministry of Health of Burkina Faso for over 10 years. In 2010, the Centre MURAZ is firmly committed to organizational reforms, better pre-production knowledge to the development of new strategies for improving the health of our populations.
Centre MURAZ has developed malaria vaccine trial site at Nonoro (North - Est of Burkina). It has also many projects on bacterial meningitis, in particular a project to evaluate the best scheme to immunize children less than 5 year of age against pneumococcus with PCV-13 in collaboration with AMP (Agence de Médecine Préventive) and PFIZER laboratories. Centre MURAZ has several research focused on HIV/AID, Tuberculosis and Reproductive Health.
The Centre Pasteur du Cameroun in Yaounde is a Cameroonian public institution which is rattached to the Ministry of Public Health. It has four missions 1) services – clinical biology, vaccination, food and water quality testing- , 2) public health – surveillance and epidemiology surveys for cholera, yellow fever, measles, polio, influenza, meningitis, tuberculosis in partnership with Ministry of Public Health and WHO, 3) research on HIV, Buruli ulcer, hepatitis, malaria, arboviruses, antimicrobial resistance, 4) training and education of health specialists. The CPC receives support from various funding agencies: Cameroon Ministry ofPublic Health, French Agence Nationale de Recherche sur le Sida et les Hépatites, French Agence Nationale de Recherche, Agence Française de Développement US Human Health Services, World Trade Organisation. It has two main sites in Cameroon, Yaounde and Garoua and a total of around 200 employees.
The Clinical Research Center-Clinical Epidemiology (Centre d'Investigation Clinique-Epidémiologie Clinique, CIC-EC) of Saint-Etienne was created in February 2003. The major assignments entrusted were to develop the methodological aid and IT support to multicentric clinical trials and clinical epidemiological research taking on all or part of this research work. The CIC-EC was therefore aimed at clinical research development particularly within labelled teams of the CHU of Saint-Etienne. In 2008, the CIC-EC has been expanded to new fields of clinical research as cancer and vaccinology. The CIC-EC Vaccinology has been developed by the Pr. F. Lucht (medical doctor in infectious diseases) and the Dr. S. Paul (immunologist and expert in vaccinology). In 2009, the CIC-EC Vaccinology has been labelled by ANRS (French network for HIV vaccine research) and REIVAC (French network of clinical investigators in Vaccinology). The CIC has participated in more than 20 clinical trials in the field of vaccine development both with academic labs and companies. The expertise of the CIC-EC Vaccinology renamed as CIC1408 in 2013 is the evaluation of mucosal vaccines. In 2014, the REIVAC network has been labelled by the F-Crin network to develop excellence in the field of Vaccinology in Europe.
CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. Focusing principally on technological research, CEA has always relied on fundamental research known for its excellence in both physical and life sciences. This fundamental research accounts for about one third of the organisation's activities and contributes to all its activities - defence, energy and information and health technologies. Research in progress at the iMETI is focused on identifying what makes emergent diseases different, on the lessons to be learned from pathophysiological studies on these diseases in terms of understanding new biological functions, and on building new therapeutic strategies. The iMETI’s work on new therapies involves research into the therapeutic use of somatic stem cells and genetic modifications in these cells. The research carried out at the Institute of Emerging Diseases and Innovative Therapy is targeted on two disease models – HIV/Emerging Viruses, and Prions. Work is now being oriented towards developing new vaccine-based therapies for HIV infection and studying the recently-discovered links between and prion diseases and Alzheimer’s disease. The creation of this Institute is a logical move forward from the HIV and prion research conducted at the CEA’s Fontenay-aux-Roses centre. Genetic and cell therapy has been added as a logical progression of the Fontenay-aux-Roses site’s expertise in HIV-derived vectors for preclinical studies, which is a key step as a prerequisite to the use of gene therapy protocols in clinical practice. The iMETI employs 44 permanent research staff in its three core departments: HIV/Emerging viruses and Immunotherapy, Prion diseases and Neurogeneration, and Innovative Therapies.
COREVAC is a consortium of research laboratories and clinical services aimed at networking multidisciplinary approaches in vaccinology, from bench to bedside, taking into account society concerns and the public health priorities. Strenghtened by 20 European research vaccine programs, COREVAC is building French research consortium & platforms in vaccinology to cover preclinical research (antigen design & formulation, animal models), vaccine immunology (memory, tools), clinical research (Phase I to phase IV, vaccine cohorts and specific elderly or immunosupressed niche), as well as epidemiological and socioeconomical research.
EFS is the French blood transfusion organisation, guaranteeing France's self-sufficiency in blood supply for a million patients each year, thanks to the generosity of donors. EFS, manages the collection, processing, screening and distribution activities of blood products, and supplies over 2000 health establishments throughout France. EFS is also the leading supplier of cell and tissue therapy products to health-care establishments, with its network of 18 dedicated platforms and tissue banks. Every year, 60% of the tissues (corneas, bones, heart valves, vessels, skin, etc.) collected by health-care establishments are processed and stored at the EFS's tissue banks. Beyond its core purpose, EFS also develops innovative research projects, in the field of blood transfusion, immunology, cell therapy and advanced cell medicinal products. The up-grading of five cell therapy facilities to reach GMP grade is planed, and EFS should soon become a pharmaceutical company for the manufacturing of cell therapy products.
Founded in 1997, the Institute of Research in Health Sciences (Institut de Recherche en Sciences de la santé - IRSS) is one of the 4 specialized units of the National Centre of Scientific and Technologic Research. The research unit on HIV/AIDS and reproductive health is part of IRSS and was created in 2006. It aims to ensure coherence in and to provide support to research on HIV/AIDS and reproductive health. In the field of reproductive health IRSS conducted a study on female genital mutilation practices in collaboration with ICRH. It also did research on the impact of the abolition of user fees on the utilization of health services and the impact of the gratuity of emergency neonatal and obstetric care on maternal mortality. IRSS also implemented a Demographic and Epidemiologic Surveillance System in Kaya (KaDESS) in the northern part of Burkina Faso. This surveillance system covers a population of 54,785 people and serves as a platform for research on HIV, reproductive health and health systems.
The Butantan Institute, affiliated with the Secretary of Health of São Paulo is one of the largest biomedical research centers in the world, a major producer of sera and vaccines in Brazil, among them, diphtheria, tetanus, pertussis, hepatitis B and influenza. The Institute carries out studies in basic and applied research in Biology and Biomedicine, related directly or indirectly to public health and produces vaccines and sera for prophylactic and curative usages. The Butantan conducts scientific missions at home and abroad for the World & Pan American Health Organizations, UNICEF and UNO, combating outbreaks. Moreover, Butantan organizes advanced training for technicians and integrates harmonious development of scientific and technological research. The quality and credibility of the work developed in the institution reflect the expertise of its scientists and technicians, which in its 111 years make the reputation of Instituto Butantan.
The CIRI is an International Center for Infectiology Research that promotes an integrated approach to study a broad range of host-pathogen interactions through a multidisciplinary perspective involving microbiology, virology, immunology and clinical research. The CIRI translates its scientific discoveries into clinical or industrial applications, at least up to early proofs of concept. The CIRI was created in January 2013, by clustering around 280 research community people, organized in 20 founding teams with strong expertise on infectious agents, associated diseases and host responses. They collectively address (i) integrative immunology for vaccination and biotherapies, (ii) metabolo-infectiology and non-communicable diseases, (iii) nosocomial infections, (iv) emerging and highly pathogenic infections, and (v) consequences of co-infections in humans. The CIRI strengthens the links between Lyon academic and clinical research communities through strong partnership with operators boosting innovation and pre-industrial development such as Finovi foundation, LyonBiopole and BIOASTER.
The International Vaccine Institute (IVI) is an international nonprofit organization that was founded on the belief that the health of children in developing countries can be dramatically improved by the use of new and improved vaccines. Working in collaboration with the international scientific community, public health organizations, governments, and industry, IVI is involved in all areas of the vaccine spectrum – from new vaccine design in the laboratory to vaccine development and evaluation in the field to facilitating sustainable introduction of vaccines in countries where they are most needed. Created initially as an initiative of the United Nations Development Programme (UNDP), IVI began formal operations as an independent international organization in 1997 in Seoul, Republic of Korea. Currently, IVI has 35 countries and the World Health Organization (WHO) as signatories and/or state parties to its Establishment Agreement. The Institute has a unique mandate to work exclusively on vaccine development and introduction specifically for people in developing countries, with a focus on neglected diseases affecting these regions.
Intravacc is a biopharmaceutical company that is dedicated to developing vaccines. We work on safe, effective and affordable vaccine concepts in order to find sustainable solutions to improve public health worldwide. Intravacc (Institute for Translational Vaccinology) is based in Bilthoven, The Netherlands. We operate under the Dutch Ministry of Public Health, Welfare and Sport. Intravacc has a long history in developing vaccines. It promotes public health by developing vaccines from the laboratory to clinical study in man. To achieve this mission, our aim is to substantially reduce development risks and costs of new vaccines by bridging the translational gap between laboratory bench and market.
The Paul-Ehrlich-Institut is an institution of the Federal Republic of Germany. It reports to the Bundesministerium für Gesundheit (Federal Ministry of Health). Most of its activities relate to the various duties laid down in German and European medicinal product legislation, such as for example the approval of clinical trials and the marketing authorisation of particular groups of medicinal products. Since its foundation more than a hundred years ago the Paul-Ehrlich-Institut has concentrated on biological medicinal products: vaccines for humans and animals, medicinal products containing antibodies, allergens for therapy and diagnostics, blood and blood products and, more recently, tissue and medicinal products for gene therapy, somatic cell therapy and xenogenic cell therapy, i.e. for processes in the latest forms of biomedical treatment.
These approval and marketing authorisation activities, together with the recording and assessment of undesirable effects (pharmacovigilance), are aimed at making medicinal products with a positive benefit/risk ratio available to the population. The Paul-Ehrlich-Institut also performs official experimental batch testing independently of the manufacturer, thus providing an essential contribution to the safety of biological medicinal products. A similar task is carried out by a testing laboratory at the Paul-Ehrlich-Institute, primarily for in vitro diagnostic medical devices that are used for the safety of blood and blood products.
The Institution's own experimental research in the field of life sciences is an indispensable basis for the fulfilment of these duties. According to the assessment of the Wissenschaftsrat (the scientific advisory body of the German Federal Government) in 2000, this research makes a decisive contribution to the competence of the Paul-Ehrlich-Institut. It is also an essential requirement for being able to provide advisory functions at the national (Federal Government, German states) and international level (World Health Organization, European Medicines Agency, European Commission, Council of Europe and others) in a responsible and expert fashion.
The research unit SPHERE (Science, Philosophy, History CNRS UMR7219), associated to Paris 7 University and located on its precincts, was born in 2009 from the merging of two units: the Centre for the History of Arabic Sciences and Medieval Philosophies, created in 1972, and the Epistemological and Historical Research Unit on the exact sciences and scientific institutions, created in 1984.
The SPHERE laboratory studies mathematical, physico-chemical and biological science from an interdisciplinary perspective, including philosophy and social sciences, over time and across cultural areas (Arab and Muslim world, Japan and China, Subsaharan Africa).
SSI is a public enterprise under the Danish Ministry of Health. For more than 100 years SSI’s main task has been to secure the preparedness towards infectious diseases and congenital disorders. The tasks have been expanded, and today, SSI is an international research, production and service enterprise. Statens Serum Institut (SSI) is responsible for research-based health surveillance, rational use of IT in the Danish healthcare system and prevention and control of infectious diseases, biological threats and congenital disorders.
The Centre for the Evaluation of Vaccination (CEV) is headed by Prof. Pierre Van Dammeand was established in 1994.
CEV has until present conducted more than 120 vaccine trials (Phase 1-4, with all kinds of vaccines and in all age groups) and more than 20 policy research projects related to vaccination. The Centre has been recognised by the World Health Organization as a WHO Collaborating Centre for the control of viral hepatitis since 1996. There is systematic collaboration with the Centre for Statistics (CenStat) at HasseltUniversity for this research on infectious diseases and vaccination. Evaluation of vaccinations must be considered at large, starting from immunogenicity, effectiveness and safety of a vaccine, the long-term persistence of vaccine-induced antibodies, the impact on the dynamics of an infection, the success of a vaccination programme, and its efficiency (protective efficacy) and economic impact. With regards to technical vaccine research, there is a continuous cooperation with the R&D departments of the major vaccine producers. Regarding policy-oriented research, regional and federal government, and the EU and foreign governmental authorities solicit the expertise of the CEV. For immunological spin-offs there is close collaboration with LEH (immunological memory after vaccination), and for the serological aspects, the expertise of LMM of Prof. Herman Goossens is called upon. At the same time, CEV offers its Phase I vaccine research platform to other research groups inside and outside the University of Antwerp and the University Hospital of Antwerp (e.g., within the framework of therapeutic vaccination as described earlier) in the coming years, the vaccination study platform will be enhanced with a shortened ‘bedside-to-bench’ delivery time, in order to quickly adjust the vaccine development process.